Heart Failure
The Colorado Prevention Center focuses on heart failure across a range of clinical settings, including patients who are intolerant of or not eligible for steroidal mineralocorticoid receptor antagonists, as well as those hospitalized with worsening cardiac disease.
- HFrEF
- HFmrEF
- HFpEF
Its research activity includes both chronic and acute presentations of heart failure, with attention to clinical outcomes and symptom burden in hospitalized populations.
Cardiovascular Pharmacotherapy
Clinical studies supported by the sponsor examine finerenone in cardiovascular care, with interest in its role for patients with heart failure who have limited treatment options.
- Non-steroidal mineralocorticoid receptor antagonism
- SGLT2 inhibitors
- Combination therapy
The sponsor’s therapeutic focus includes medication strategies used alongside usual care in both outpatient and inpatient cardiology settings.
Acute Cardiac Care
Research activity also centers on hospitalized heart failure, including patients with acute decompensated heart failure and those requiring early treatment decisions during admission.
- Inpatient heart failure management
- Acute decompensation
- Clinical outcome assessment
This area reflects interest in treatment approaches that address short-term events and longer-term cardiovascular risk after hospitalization.
Patient-Reported Outcomes
The sponsor’s trials incorporate health status and symptom-focused measures in heart failure, including assessment of daily symptom burden and functional impact.
- Kansas City Cardiomyopathy Questionnaire
- Symptom burden
- Quality of life
These outcomes align with the sponsor’s interest in both survival-related endpoints and the lived experience of patients with cardiac disease.
